Navigation Links
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Date:5/8/2008

term studies used the Hamilton Rating Scale for Anxiety (HAM-A)* as the primary assessment of anxiety symptoms.(5-8)

Study 12 was a long-term, multicenter, randomized-withdrawal, parallel- group, placebo-controlled, Phase III study that comprised four phases: an enrollment period of up to 28 days, an open-label run-in treatment period of four to eight weeks, an open-label stabilization treatment period of 12 to 18 weeks, and a randomized-withdrawal treatment period of up to 52 weeks. The SEROQUEL XR dose was flexible: 50 mg, 150 mg, or 300 mg once daily, based on the clinical judgment of the investigator. In this longer-term study, the primary assessment was time from randomization to an anxiety event.(8)

In 2007, SEROQUEL XR was approved in the U.S. for the treatment of schizophrenia in adult patients and for maintenance treatment of schizophrenia in adult patients. SEROQUEL XR is currently not approved for the treatment of bipolar disorder. In January 2008, AstraZeneca announced the submission of two separate sNDAs to the FDA for SEROQUEL XR to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder. In February 2008, AstraZeneca filed a sNDA for SEROQUEL XR to seek approval for the treatment of MDD as monotherapy, adjunct therapy, and maintenance therapy. The FDA has not completed its review of these submissions.

IMPORTANT SAFETY INFORMATION FOR SEROQUEL XR

SEROQUEL XR is indicated for the acute and maintenance treatment of schizophrenia. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL XR is not approved for the treatment of patients with dementia-related psycho
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)... their function like a radio dial, not an on/off,l...une disease may develop,late in life, MEMPHIS, ...e Children,s,Research Hospital study shows that T ... use simple on/off switches to govern the cellular...nction. Rather, they,possess sophisticated molecul...
(Date:5/12/2008)... 12 /- Arbios Systems, Inc....he Company has received,approval from the U.S. Foo...ional Device Exemption ("IDE") to begin the pivota...real (outside the body) liver assist,device for bl... from,chronic liver disease., "We are pleased to ...
(Date:5/12/2008)...rt 3 Demonstrated Improvement in T-Cell Responses ...al of HspE7, SAN DIEGO, May 12 /PRNewswire-FirstC...: NVN) today announced positive immunological data...ical trial of its lead product,candidate, HspE7, i..., or,CIN, a precursor to cervical cancer. HPV 16 E...
(Date:5/9/2008).../PRNewswire-USNewswire/ -- Many strong acting pain...an include nausea and,vomiting with short-term use...symptoms can lead patients to discontinue treatmen...ent for physicians. The novel investigational,medi...ic, provided pain,relief for patients with fewer g...
Breaking Medicine Technology:St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 2New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 3New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR 4Registry unveils real world data on novel excel stent 15505 1Registry unveils real world data on novel excel stent 15505 2Study finds support for PCI in unprotected left main disease 15501 1Study finds support for PCI in unprotected left main disease 15501 2Study finds support for PCI in unprotected left main disease 15501 3Response Biomedical Corporation Reports 2007 Financial Results 15498 1Response Biomedical Corporation Reports 2007 Financial Results 15498 2Response Biomedical Corporation Reports 2007 Financial Results 15498 3Response Biomedical Corporation Reports 2007 Financial Results 15498 4Response Biomedical Corporation Reports 2007 Financial Results 15498 5China Medicine Corporation to Present at Brean Murray Carret 26 Co Mainland China Investor Tour 15494 1China Medicine Corporation to Present at Brean Murray Carret 26 Co Mainland China Investor Tour 15494 2
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
... tissue abnormalities, or lesions, that typically ...nfected with multiple genotypes// of the human pap...ing to a study published in the July issue of Canc...ion. Although doctors have known that the cervica...
...ter is among 10 institutions selected to oversee i...ving interventions for critical trauma// and sudde...th has joined with other U.S. and Canadian agencie...on Outcomes Consortium (ROC) and establish federal...
...ttle super bugs, including MRSA, has found its way...d the news as Tygacil, is one of the few new antib...rs. Micro organisms have undergone mutations that...sistance to the existing antibiotics, leading to w...
...sleep would probably help the human brain to enhan...arned facts.// It was reported that previous stud...declarative memories, like the steps of learning t... It was explained that the new experiment focuses ...
Other Medicine News:Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 2Health News:Higher Risk for Cervical Cancer Seen Among Women Infected with Multiple HPV Types 3Health News:Medical Center to Test Methods of Improving Cardiac Arrest, Trauma Survival 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Sleep Essential For A Strong Memory 2
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
...ence laboratory and a worldwide leader in innovati...s an extensive test menu of highly complex and uni...gy. Owned by the University of Utah, ARUP Laborato...'s university teaching hospitals and children's ho...
Medicine Products: